88 related articles for article (PubMed ID: 21115778)
1. Should A1C targets be individualized for all people with diabetes? Arguments for and against.
Teoh H; Home P; Leiter LA
Diabetes Care; 2011 May; 34 Suppl 2(Suppl 2):S191-6. PubMed ID: 21525454
[No Abstract] [Full Text] [Related]
2. The trials and tribulations of the University Group Diabetes Program 2: lessons and reflections.
Meinert C
J R Soc Med; 2019 Dec; 112(12):503-511. PubMed ID: 31825277
[No Abstract] [Full Text] [Related]
3. Looking for clues in the hypnogram-the human eye and the machine.
Pevernagie DA; Arnardottir ES
Sleep; 2024 Mar; 47(3):. PubMed ID: 38219052
[No Abstract] [Full Text] [Related]
4. Evolution of Type 2 Diabetes Management from a Glucocentric Approach to Cardio-Renal Risk Reduction: The New Paradigm of Care.
Jacob S; Krentz AJ; Deanfield J; Rydén L
Drugs; 2021 Aug; 81(12):1373-1379. PubMed ID: 34302636
[TBL] [Abstract][Full Text] [Related]
5. Predicting 5- and 10-Year Mortality Risk in Older Adults With Diabetes.
Griffith KN; Prentice JC; Mohr DC; Conlin PR
Diabetes Care; 2020 Aug; 43(8):1724-1731. PubMed ID: 32669409
[TBL] [Abstract][Full Text] [Related]
6. Diabetes: the place of new therapies.
Dhatariya K
Ther Adv Endocrinol Metab; 2019; 10():2042018818807599. PubMed ID: 30800266
[TBL] [Abstract][Full Text] [Related]
7. Effects of Severe Hypoglycemia on Cardiovascular Outcomes and Death in the Veterans Affairs Diabetes Trial.
Davis SN; Duckworth W; Emanuele N; Hayward RA; Wiitala WL; Thottapurathu L; Reda DJ; Reaven PD;
Diabetes Care; 2019 Jan; 42(1):157-163. PubMed ID: 30455335
[TBL] [Abstract][Full Text] [Related]
8. Characteristics Associated With Decreased or Increased Mortality Risk From Glycemic Therapy Among Patients With Type 2 Diabetes and High Cardiovascular Risk: Machine Learning Analysis of the ACCORD Trial.
Basu S; Raghavan S; Wexler DJ; Berkowitz SA
Diabetes Care; 2018 Mar; 41(3):604-612. PubMed ID: 29279299
[TBL] [Abstract][Full Text] [Related]
9. How Can We Realize the Clinical Benefits of Continuous Glucose Monitoring?
Ajjan RA
Diabetes Technol Ther; 2017 May; 19(S2):S27-S36. PubMed ID: 28541132
[TBL] [Abstract][Full Text] [Related]
10. Closing the Loop.
Nimri R; Murray N; Ochs A; Pinsker JE; Dassau E
Diabetes Technol Ther; 2017 Feb; 19(S1):S27-S41. PubMed ID: 28192023
[No Abstract] [Full Text] [Related]
11. Insulin Dose and Cardiovascular Mortality in the ACCORD Trial.
Siraj ES; Rubin DJ; Riddle MC; Miller ME; Hsu FC; Ismail-Beigi F; Chen SH; Ambrosius WT; Thomas A; Bestermann W; Buse JB; Genuth S; Joyce C; Kovacs CS; O'Connor PJ; Sigal RJ; Solomon S;
Diabetes Care; 2015 Nov; 38(11):2000-8. PubMed ID: 26464212
[TBL] [Abstract][Full Text] [Related]
12. Effects of intensive glycaemic control on ischaemic heart disease: analysis of data from the randomised, controlled ACCORD trial.
Gerstein HC; Miller ME; Ismail-Beigi F; Largay J; McDonald C; Lochnan HA; Booth GL;
Lancet; 2014 Nov; 384(9958):1936-41. PubMed ID: 25088437
[TBL] [Abstract][Full Text] [Related]
13. Hypoglycemia as a driver of cardiovascular risk in diabetes.
Moheet A; Seaquist ER
Curr Atheroscler Rep; 2013 Sep; 15(9):351. PubMed ID: 23881546
[TBL] [Abstract][Full Text] [Related]
14. Individualizing targets and tactics for high-risk patients with type 2 diabetes: practical lessons from ACCORD and other cardiovascular trials.
Riddle MC; Karl DM
Diabetes Care; 2012 Oct; 35(10):2100-7. PubMed ID: 22996182
[No Abstract] [Full Text] [Related]
15. Shadow of diabetes over cardiovascular disease: comparative quantification of population-attributable all-cause and cardiovascular mortality.
Bozorgmanesh M; Hadaegh F; Sheikholeslami F; Ghanbarian A; Azizi F
Cardiovasc Diabetol; 2012 Jun; 11():69. PubMed ID: 22704235
[TBL] [Abstract][Full Text] [Related]
16. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
Inzucchi SE; Bergenstal RM; Buse JB; Diamant M; Ferrannini E; Nauck M; Peters AL; Tsapas A; Wender R; Matthews DR
Diabetologia; 2012 Jun; 55(6):1577-96. PubMed ID: 22526604
[No Abstract] [Full Text] [Related]
17. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
Inzucchi SE; Bergenstal RM; Buse JB; Diamant M; Ferrannini E; Nauck M; Peters AL; Tsapas A; Wender R; Matthews DR; ;
Diabetes Care; 2012 Jun; 35(6):1364-79. PubMed ID: 22517736
[No Abstract] [Full Text] [Related]
18. Death during intensive glycemic therapy of diabetes: mechanisms and implications.
Cryer PE
Am J Med; 2011 Nov; 124(11):993-6. PubMed ID: 22017775
[No Abstract] [Full Text] [Related]
19. Counterpoint: Intensive glucose control and mortality in ACCORD--still looking for clues.
Riddle MC
Diabetes Care; 2010 Dec; 33(12):2722-4. PubMed ID: 21115778
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
